http://orcid.org/0000-0001-6430-2276
References
- Tziomalos K, Athyros VG, Paschos P, et al. Nonalcoholic fatty liver disease and statins. Metabolism. 2015;64(10):1215–1223.
- Browning JD. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology. 2006;44(2):466–471.
- Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126(5):1287–1292.
- Bjornsson ES. Hepatotoxicity of statins and other lipid-lowering agents. Liver Int. 2017;37(2):173–178.
- Eslami L, Merat S, Malekzadeh R, et al. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev. 2013;27(12):CD008623.
- Imprialos KP, Stavropoulos K, Doumas M, et al. The potential role of statins in treating liver disease. Expert Rev Gastroenterol Hepatol. 2018;12(4):331–339.
- Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20.
- Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547–555.
- Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865–873.
- Sonmez A, Nikolic D, Dogru T, et al. Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. J Clin Lipidol. 2015;9(4):576–582.
- Purnak T, Efe C, Beyazit Y, et al. Recent insights into the relationship between inflammatory liver diseases and atherosclerosis. J Investig Med. 2011;59(6):904–911.
- Dongiovanni P, Petta S, Mannisto V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015;63(3):705–712.
- Bril F, Portillo Sanchez P, Lomonaco R, et al. Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: post hoc analysis of a randomized trial. J Clin Endocrinol Metab. 2017;102(8):2950–2961.
- Nascimbeni F, Aron-Wisnewsky J, Pais R, et al. Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastroenterol. 2016;3(1):e000075.
- Gao X, Nan Y, Zhao Y, et al. Atorvastatin reduces lipid accumulation in the liver by activating protein kinase A-mediated phosphorylation of perilipin 5. Biochim Biophys Acta. 2017;1862(12):1512–1519.
- Kim RG, Loomba R, Prokop LJ, et al. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15(10):1521–1530 e1528.
- Guixe-Muntet S, De Mesquita FC, Vila S, et al. Cross-talk between autophagy and KLF2 determines endothelial cell phenotype and microvascular function in acute liver injury. J Hepatol. 2017;66(1):86–94.
- Marrone G, Maeso-Diaz R, Garcia-Cardena G, et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut. 2015;64(9):1434–1443.
- Gracia-Sancho J, Garcia-Caldero H, Hide D, et al. Simvastatin maintains function and viability of steatotic rat livers procured for transplantation. J Hepatol. 2013;58(6):1140–1146.
- Janicko M, Drazilova S, Pella D, et al. Pleiotropic effects of statins in the diseases of the liver. World J Gastroenterol. 2016;22(27):6201–6213.
- Katsiki N, Athyros VG, Karagiannis A, et al. Statins and type 2 diabetes mellitus: an update after 1 year. Curr Pharm Des. 2016;22(18):2723–2725.
- Brodosi L, Marchignoli F, Petroni ML, et al. NASH: a glance at the landscape of pharmacological treatment. Ann Hepatol. 2016;15(5):673–681.
- European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59(6):1121–1140.